BioGenerator leveraged its Grants, Fundamentals, and Grants- 2-Business programs enabling KaloCyte to craft and implement three highly innovative strategies (technical differentiation, accelerating regulatory path, Federal de-risking grants) to attract expertise and...
The University System of Maryland (USM) continues to aid entrepreneurs at UMB and throughout the state, including KaloCyte, with the $10 million Maryland Momentum Fund (MMF). Click here to read the article featured in Catalyst magazine, a UMB publication.
Old Line Capital Partners has made a significant investment in KaloCyte, Inc., to extend the research and development of break-through human blood substitute ErythroMer. Click here to read the news release issued by Old Line Capital.
Months after moving to Baltimore, the company is growing its team and gaining funding from local institutions. Click here to read the article in its entirety. Stephen Babcock, assistant editor for Technical.ly, highlights the company’s recent round of investment...
June 4, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, is one of just 10 life science...
May 5, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, announced today that the National...
